Design issues in studies evaluating diagnostic tests for aspergillosis

Clinical Infectious Diseases

Volumn 41, Issue 6 SUPPL., 2005, Pages

  Marr, Kieren A ^a,b   Leisenring, Wendy ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; LUNG DISEASE; LUNG TRANSPLANTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 24644510183     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430920     Document Type: Review

References (35)

1. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003; 5:158-66.
2. Bretagne S. Molecular diagnostics in clinical parasitology and mycology: limits of the current polymerase chain reaction (PCR) assays and interest of the real-time PCR assays. Clin Microbiol Infect 2003; 9: 505-11.
3. US Food and Drug Administration. Device summary for Bio-Rad Laboratories Platelia* Aspergillus E1A. Available at: http://www.fda.gov/ cdrh/pdf2/k023857.pdf. Accessed 26 July 2005.
4. Marr KA, Balajee S, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-9.
5. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med 2002; 137: 598-602.
6. Hagdu A. The discrepancy in discrepant analysis. Lancet 1996; 348: 592-3.
7. Hagdu A. Bias in the evaluation of DNA-amplification tests for detecting Chlamydia trachomatis. Stat Med 1997; 16:1391-9.
8. Hagdu A. Discrepant analysis: a biased and an unscientific method for estimating test sensitivity and specificity. J Clin Epidemiol 1999; 52: 1231-7.
9. Miller W. Bias in discrepant analysis: when two wrongs don't make a right. J Clin Epidemiol 1998; 51:219-31.
10. Lipman H, Astles J. Quantifying the bias associated with the use of discrepant analysis. Clin Chem 1998; 44:108-15.
11. Hawkins D, Garrett J, Stephenson B. Some issues in resolution of diagnostic tests using an imperfect gold standard. Stat Med 2001; 20: 1987-2001.
12. Alonzo T, Pepe M. Using a combination of reference tests to assess the accuracy of a new diagnostic test. Stat Med 1999; 18:2987-3003.
13. Leisenring W, Pepe M, Longton G. A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med 1997; 16: 1263-81.
14. Kawamura S, Maesaki S, Noda T, et al. Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. J Clin Microbiol 1999; 37:218-20.
15. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8.
16. Ulusakarya A, Chachaty E, Vantelon JM, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1:111-6.
17. Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen j. Aspergillus antigen in serum, urine, and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 2000; 32:485-90.
18. Fortun I, Martin-Davila P, Alvarez ME, et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71:145-9.
19. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33:1504-12.
20. Siemann M, Koch-Dorfler M. The Platelia Aspergillus ELISA in diagnosis of invasive pulmonary aspergillosis (IPA). Mycoses 2001; 44: 266-72.
21. Maertens J, Verhaegen J, Lagrou K, Van Eldere I, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10.
22. Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91:311-8.
23. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186:1297-306.
24. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20:1898-906.
25. Rimek D, Kappe R. Invasive aspergillosis: results of an 8-year study [in German]. Mycoses 2002; 45(Suppl 3):18-21.
26. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184-6.
27. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121:448-57.
28. Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 125:196-202.
29. Kwak EJ, Husain S, Obman A, et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42:435-8.
30. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796-802.
31. Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77:1260-4.
32. Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet 2004; 363:325-7.
33. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004;48:1989-92.
34. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin- tazobactam. Clin Infect Dis 2004; 38:913-6.
35. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38:917-20.